The cosmetic drug and device maker posted adjusted Q4 EPS of $1.15, up 15%, but 3 cents shy of views. Allergan (AGN) product sales climbed 7.4% to $1.51 bil, in line. Sales of Botox climbed 14.3%, thanks in part to its recently approved use for treating migraine headaches. Sales of prescription eye drugs, its largest business, rose 7.1% to $706 mil. Allergan guided '13 EPS of $4.75-$4.83 vs. analysts' expectations for $4.74. Shares rose 1.6%.